Audited Supplier
In This Store
Founded in 2000 in the name of Dongwoo SynTech Co., Ltd. INIST ST has headed developing raw material medicine and its synthesis technology. Based on change and innovation, and love for life, INIST ST has researched and developed excellent-quality generic raw materials and new salt IMDs (incrementally modified drug) starting from cerebrovascular medicine and has supplied them domestically and overseas.
Based on the long-accumulated firm trust and technology, the company developed multiple first generic raw materials, which have led to the development of innovative new drugs such as a contrast medium for heart disease, and calcium channel blocker anticancer drug. The company’s advanced technology moves it beyond the high market barriers of developed countries into the global market such as over KRW 50 billion export to the medically advanced country of Japan.
INIST ST, in order to respond to the rapidly changing global market and more complicated diseases, continues its research with the spirit of change and innovation, and love for life.
Year of Establishment: 2000
Total Assets(USD):
Total Number of Staff: 100-500
Main Competitive Advantages: Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service
Other Competitive Advantages: INIST operates cGMP manufacturing facility, which is designed for handling high-potent materials. Various projects from lab scale to mass scale are available at INIST Osong plant. One of the projects INIST is currently working on is with a US partner, on process development and optimization. As a growing CDMO, INIST aims to achieve highest quality yet cost effectiveness, meeting all the requirements proposed by clients.
Patents and Copyrights:
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us：
Pharma Sources Insight JANUARY 2024
